期刊
THERANOSTICS
卷 7, 期 1, 页码 67-80出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.16752
关键词
prostate cancer; CD54; cancer stem cells; NOTCH1
资金
- National Natural Science Foundation of China [81672956, 81472413, 81130041, 81472679]
- Shenzhen Science and Technology Development Funds Program [CXZZ20130516153248144]
- Shenzhen Strategic Emerging Industry Development Special Funds Program [JSGG20130411091246833]
- Major Program of Scientific Research Foundation from Yunnan Provincial Department of Education [2014Z052]
- Science and Technology Program of Yunnan Province [2014RA067]
Cancer stem cells (CSCs) are considered one of the key contributors to chemoresistance and tumor recurrence. Therefore, the precise identification of reliable CSC markers and clarification of the intracellular signaling involved in CSCs remains a great challenge in fields relating to cancer biology. Here, we implemented a novel chemoresistant prostate cancer patient-derived xenograft (PDX) model in NOD/SCID mice and identified CD54 as a candidate gene among the most highly enriched gene expression profiles in prostate tumors exposed to chronic cisplatin administration. Additional in vitro and in vivo assays showed that CD54 played a critical role in the self-renewal and tumorigenesis of prostate CSCs. Moreover, silencing CD54 greatly reduced the tumorigenesis of prostate cancers both in vitro and in vivo and significantly extended the survival time of tumor-bearing mice in a prostate cancer xenograft model. Dissection of the molecular mechanism revealed that the p38-Notch1 axis was the main downstream signaling pathway in CD54-mediated regulation of CSCs in prostate cancers. Together, these results established that CD54 could be a novel reliable prostate CSC marker and provided a new potential therapeutic target in prostate cancer via CD54-Notch1 signaling.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据